HillstreaHillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020
October 1st, 2020
Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and
Orphan Products Breakthrough Summit 2020
Bridgewater, New Jersey, October 5, 2020 – Hillstream BioPharma, Inc. (“Hillstream”) today announced its participation in the Rare Diseases and Orphan Products Breakthrough Summit 2020 virtual conference hosted by the National Organization for Rare Diseases (NORD). Randy Milby, Chief Executive Officer of Hillstream, will be participating in a panel entitled “Advancing Patient Access to Care Through Drug Repurposing”.
The theme for this year’s Summit, “Entering a New Era”, will spotlight the advances made in scientific innovation, opening a new era in drug research and discovery worldwide. The two-day program will include both plenary and breakout sessions addressing contemporary issues pertinent to rare diseases, orphan products, and global public health concerns. There will be numerous opportunities for audience participation.
Details about the conference and Hillstream’s panel participation are as follows:
|2020 NORD Rare Diseases and Orphan Products Breakthrough Summit
|Thursday, October 8, 2020 – Friday, October 9, 2020
|Advancing Patient Access to Care Through Drug Repurposing
|Friday, October 9, 2020 – 1.30-2.15pm ET
|World Orphan Drug Conference USA
The panel discussion will be recorded and available on demand via NORD’s virtual platform for 30 days post conference (until November 9, 2020). Hillstream will also be available for 1:1 appointments with registered attendees during the event through NORD’s virtual conference scheduling system. Investors wishing to connect with Hillstream outside of the Rare Diseases and Orphan Products Breakthrough Summit 2020 virtual conference can book appointments directly through Hillstream’s investor relations representative, Jennifer K. Zimmons, Ph.D. firstname.lastname@example.org or +1.917.214.3514.
About Hillstream BioPharma, Inc.
Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company focused on rare cancers. By harnessing a weakness in tumors to preferentially concentrate advancing novel immune-oncology therapeutics for critical unmet needs. By harnessing a weakness in tumors to preferentially concentrate Hillstream’s QUATRAMER™ technology, we are developing targeted cancer therapies. The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into tumor’s genome. Hillstream is working to improve the lives of patients and rapidly move into the clinic to treat small cell lung cancer, soft tissue sarcoma and other unmet need rare cancers. For more information, please visit tharimmune.com.
About National Organization for Rare Diseases
NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. Please visit National Organization for Rare Diseases.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Hillstream BioPharma, Inc.
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications, Inc.
Tel: +1 917.214.3514
Source: Hillstream BioPharma, Inc.